European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

MT Newswires Live02-06 00:14

European equities traded in the US as American depositary receipts were falling sharply late Thursday morning, down 1.78% to 1,777.91 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and consumer goods company Unilever (UL), which rose 2.7% and 1%, respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and telecommunications company Nokia (NOK), which were up 0.6% and 0.4%, respectively.

The decliners from continental Europe were led by lender Banco Bilbao Vizcaya Argentaria (BBVA) and semiconductor company Sequans Communications (SQNS), which fell 6.8% and 6.7%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Grifols (GRFS), which lost 6.6% and 4.2%, respectively.

From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Akari Therapeutics (AKTX), which climbed 10% and 4.9%, respectively. They were followed by pharmaceutical companies GSK (GSK) and AstraZeneca (AZN), which advanced 2.8% and 1%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and software firm Endava (DAVA), which dropped 7.2% and 7%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and telecommunications operator Vodafone Group (VOD), which were down 5.9% each.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment